GlassScriptPhysician profile
Danilo Christopher Del Campo
NPI 1922340405
$107,909.86
in general payments reported to CMS, 2019-2025
32 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $1,829 · 2021: $24K · 2022: $5,763 · 2023: $4,028 · 2024: $22K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Consulting Fee: $8,923 · Food and Beverage: $8,403 · Travel and Lodging: $2,098 · Education: $459 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,750.00 |
| Consulting Fee | $8,922.50 |
| Food and Beverage | $8,403.12 |
| Travel and Lodging | $2,098.38 |
| Education | $459.04 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $65,423.31 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Sun Pharmaceutical Industries INC. | $21,490.91 | 2019-2025 | Ilumya |
| Epi Health, LLC | $3,365.68 | 2019-2022 | |
| Janssen Biotech, INC. | $3,315.10 | 2020-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $3,032.52 | 2019-2025 | Rinvoq, Skyrizi |
| Medimetriks Pharmaceuticals, INC. | $2,239.81 | 2020-2023 | Neo-Synalar |
| Leo Pharma INC. | $1,569.69 | 2021-2025 | Adbry |
| Amgen INC. | $1,471.62 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $879.54 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $869.74 | 2020-2025 | Cabtreo, Arazlo, Jublia |
| Mayne Pharma Commercial LLC | $609.26 | 2019-2025 | |
| Lilly USA, LLC | $502.09 | 2019-2025 | Ebglyss, Taltz |
| Journey Medical Corporation | $427.19 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $346.63 | 2019-2025 | |
| Celgene Corporation | $315.12 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $314.90 | 2020-2024 | Dupixent |
| Ucb, INC. | $313.49 | 2020-2025 | Bimzelx |
| Incyte Corporation | $295.38 | 2022-2025 | Opzelura |
| Genzyme Corporation | $174.99 | 2019-2025 | |
| Vyne Pharmaceuticals INC. | $167.57 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $132.08 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.19 | 2022-2024 | Sotyktu |
| Prugen, INC. Pharmaceuticals | $121.17 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $87.39 | 2023-2024 | Zoryve |
| Revance Therapeutics, INC. | $86.08 | 2024 | Daxxify |
| Taro Pharmaceuticals USA, INC. | $78.73 | 2019 | |
| Botanix Sb INC | $53.49 | 2025 | Sofdra |
| Encore Dermatology INC. | $47.99 | 2019-2020 | |
| Almirall LLC | $16.88 | 2020 | |
| Aclaris Therapeutics, INC. | $16.66 | 2019 | |
| Mission Pharmacal Company | $16.63 | 2019 | |
| Organon LLC | $4.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Del Campo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.